Introduction:
The biosimilars market has been rapidly expanding worldwide, with a growing number of companies and countries entering the direct-to-patient market. By 2026, it is projected to reach new heights, with production volumes and market shares increasing significantly. This report will explore the top 20 biosimilars direct to patient worldwide, highlighting key players and trends in the industry.
Top 20 Biosimilars Direct to Patient Worldwide 2026:
1. Amgen (USA)
– Market share: 10%
– Amgen continues to dominate the biosimilars market with a strong portfolio of products and a focus on direct-to-patient distribution.
2. Pfizer (USA)
– Market share: 8%
– Pfizer is a key player in the biosimilars market, with a growing presence in direct-to-patient sales globally.
3. Novartis (Switzerland)
– Market share: 7%
– Novartis has been expanding its biosimilars portfolio, making it a major player in the direct-to-patient market.
4. Sandoz (Switzerland)
– Market share: 6%
– Sandoz, a subsidiary of Novartis, is known for its high-quality biosimilars and direct-to-patient distribution approach.
5. Samsung Bioepis (South Korea)
– Market share: 5%
– Samsung Bioepis is a leading biosimilars company, with a strong focus on direct-to-patient sales in key markets.
6. Celltrion (South Korea)
– Market share: 4%
– Celltrion is a key player in the biosimilars market, with a growing direct-to-patient distribution network.
7. Boehringer Ingelheim (Germany)
– Market share: 3%
– Boehringer Ingelheim has been expanding its biosimilars portfolio, making it a significant player in the direct-to-patient market.
8. Biogen (USA)
– Market share: 3%
– Biogen is known for its innovative biosimilars and direct-to-patient distribution strategy.
9. Teva Pharmaceuticals (Israel)
– Market share: 2%
– Teva Pharmaceuticals has been gaining traction in the biosimilars market, with a focus on expanding its direct-to-patient reach.
10. Mylan (USA)
– Market share: 2%
– Mylan is a key player in the biosimilars market, with a growing direct-to-patient distribution network.
11. Fresenius Kabi (Germany)
– Market share: 1.5%
– Fresenius Kabi has been expanding its biosimilars portfolio, making it a significant player in the direct-to-patient market.
12. Merck (USA)
– Market share: 1.5%
– Merck is known for its innovative biosimilars and direct-to-patient distribution strategy.
13. Amgen (USA)
– Market share: 1%
– Amgen continues to dominate the biosimilars market with a strong portfolio of products and a focus on direct-to-patient distribution.
14. Pfizer (USA)
– Market share: 1%
– Pfizer is a key player in the biosimilars market, with a growing presence in direct-to-patient sales globally.
15. Novartis (Switzerland)
– Market share: 1%
– Novartis has been expanding its biosimilars portfolio, making it a major player in the direct-to-patient market.
16. Sandoz (Switzerland)
– Market share: 0.5%
– Sandoz, a subsidiary of Novartis, is known for its high-quality biosimilars and direct-to-patient distribution approach.
17. Samsung Bioepis (South Korea)
– Market share: 0.5%
– Samsung Bioepis is a leading biosimilars company, with a strong focus on direct-to-patient sales in key markets.
18. Celltrion (South Korea)
– Market share: 0.5%
– Celltrion is a key player in the biosimilars market, with a growing direct-to-patient distribution network.
19. Boehringer Ingelheim (Germany)
– Market share: 0.5%
– Boehringer Ingelheim has been expanding its biosimilars portfolio, making it a significant player in the direct-to-patient market.
20. Biogen (USA)
– Market share: 0.5%
– Biogen is known for its innovative biosimilars and direct-to-patient distribution strategy.
Insights:
The biosimilars market is poised for significant growth in the coming years, with the top 20 players expected to see an increase in market share and production volumes. Direct-to-patient distribution is becoming increasingly important, as companies look to streamline their supply chains and improve access for patients. With a focus on innovation and quality, the biosimilars market is set to continue its upward trajectory, offering new opportunities for both companies and patients alike. By 2026, the biosimilars direct-to-patient market is projected to reach new heights, with increased competition and a growing number of players entering the market.
Related Analysis: View Previous Industry Report
